Skip to main content
Tissue Microarray Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, China, UK - Size and Forecast 2024-2028

Tissue Microarray Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, China, UK - Size and Forecast 2024-2028

Published: Oct 2024 139 Pages SKU: IRTNTR71521

Market Overview at a Glance

$2.25 B
Market Opportunity
5.8%
CAGR
5.4
YoY growth 2023-2024(%)

Tissue Microarray Market Size 2024-2028

The tissue microarray market size is forecast to increase by USD 2.25 billion at a CAGR of 5.8% between 2023 and 2028.

  • The tissue microarray (TMA) market is experiencing significant growth due to the increasing number of cancer cases worldwide. This trend is driven by the rising popularity of personalized medicines, which require the analysis of large numbers of tissue samples. However, the high cost of instruments used in TMA technology remains a challenge for market growth. The use of TMAs in research and diagnostics is expected to increase, as they offer several advantages such as reduced sample size, improved data consistency, and increased throughput. Additionally, the ability to perform multiple assays on a single TMA slide further enhances its value In the healthcare industry.
  • Overall, the TMA market is poised for steady growth In the coming years, as the demand for personalized medicines continues to rise and technological advancements make TMAs more accessible and cost-effective.

    • What will be the Size of the Tissue Microarray Market During the Forecast Period?

    Tissue Microarray Market Size

     Request Free Sample

  • The Tissue Microarray (TMA) market is a significant segment of molecular diagnostics, playing a pivotal role in molecular pathology and cancer research. TMAs enable the analysis of gene expression and protein localization in multiple tissue samples using molecular markers, facilitating the identification of biomarkers for clinical outcomes, therapeutic targets, and prognostic indicators. TMAs are instrumental in oncology research, particularly in understanding tumor heterogeneity and drug efficacy in clinical settings. TMAs are utilized in various clinical applications, including immunohistochemistry, DNA and mRNA analysis, protein expression analysis, and high-throughput screening. Spectroscopic analysis and automated analysis further enhance the capabilities of TMAs in biotechnology.
  • TMAs are prepared using paraffin blocks and tissue cores, and their applications extend to drug discovery and cancer burden assessment across various clinical conditions, such as prostate cancer. The TMA market is driven by the increasing demand for personalized medicine and the need for innovative pathology solutions In the biopsy process.

    • How is this Tissue Microarray Industry segmented and which is the largest segment?

    The tissue microarray industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

    • End-user
      • Hospitals
      • Clinics
      • Diagnostics centers
    • Geography
      • North America
        • Canada
        • US
      • Europe
        • Germany
        • UK
      • Asia
        • China
      • Rest of World (ROW)

      By End-user Insights

      • The hospitals segment is estimated to witness significant growth during the forecast period.

      The hospitals segment represents a substantial end-user base In the market due to their crucial role in cancer diagnosis and research. Tissue microarrays enable hospitals to analyze multiple tumor samples concurrently on a single slide, accelerating high-throughput examination of proteins and genes vital for cancer diagnosis. This feature is indispensable in oncology, where timely and precise assessment of biomarkers influences therapeutic decisions. Furthermore, hospitals preserve archival tissue blocks for extended durations, often up to 20 years, offering a vast reservoir of samples for tissue microarray construction. This extensive availability of samples bolsters the potential for retrospective studies linked to clinical outcomes, reinforcing the significance of tissue microarrays in clinical settings.

      Tissue microarrays facilitate molecular pathology, including gene expression analysis, protein localization, and molecular marker identification. They are instrumental in oncology research, tumor heterogeneity studies, and drug efficacy assessments. Incorporating automation, imaging techniques, data analysis, and precision medicine, tissue microarrays contribute to cancer incidence reduction, biomarker research, drug development, and clinical trials. Applications include antibodies, digital pathology, neurology, cardiology, infectious diseases, and immunohistochemistry. Tissue microarrays consist of paraffin blocks, tissue cores, and DNA analysis, enabling mRNA analysis, protein levels assessment, and automated analysis. They cater to cancer prevalence studies, diagnostic methods, and array-based technology, focusing on disease genes, heterogeneous cancers, and cancer patient cases.

      Tissue microarrays are integral to proteomics and genomics, microarray techniques, lead discovery, clinical assessment, and fluorescent in-situ hybridization. They support frozen tissue array, DNA microarray, next-generation sequencing, Northern blotting, Western blotting, gene expression profiling, SNP detection, comparative genomic hybridization, sequencing bioinformatics, and drug discovery applications. Tissue microarrays play a pivotal role in cancer treatment, enhancing diagnostic capabilities and facilitating personalized medicine.

      Tissue Microarray Market Size

      Get a glance at the  Tissue Microarray Industry report of share of various segments Request Free Sample

      The Hospitals segment was valued at USD 2.69 billion in 2018 and showed a gradual increase during the forecast period.

      Regional Analysis

      • North America is estimated to contribute 34% to the growth of the global market during the forecast period.

      Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

      Tissue Microarray Market Share by Geography

      For more insights on the market share of various regions, Request Free Sample

      The Tissue Microarray (TMA) market in North America is experiencing significant growth due to substantial investments in healthcare research and testing In the US. Pharmaceutical companies' increasing focus on drug discovery and development is another driving factor. With a high incidence of chronic diseases, particularly cancer, the demand for cancer research and diagnostics is increasing, necessitating the use of advanced molecular biology techniques such as TMAs. TMAs play a crucial role in molecular pathology, including gene expression analysis, protein localization, and biomarker discovery. They are used extensively in oncology research, clinical outcomes assessment, therapeutic targets identification, and prognostic indicators determination.

      TMAs facilitate high-throughput screening, imaging techniques, data analysis, and precision medicine, contributing to cancer prevalence studies and diagnostic methods development. Array-based technology, including DNA and mRNA analysis, protein levels assessment, and automated analysis, are integral to TMA applications. The market is also driven by the need for personalized medicine, cancer patient case studies, and the integration of proteomics and genomics in drug discovery and clinical assessment. TMAs are utilized in various clinical settings, including cancer burden assessment, drug efficacy testing, and biologics development. Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), and digital pathology are some of the key techniques used in TMA applications.

      The market encompasses various sectors, including biomarker research, drug development, clinical trials, antibodies, and diagnostic facilities. Tissue microarrays are essential tools for healthcare diagnostic facilities, enabling the analysis of paraffin blocks, tissue cores, DNA, and mRNA. The market is poised for continued growth due to the increasing importance of tissue microarrays in cancer research, biopsy, drug discovery, and cancer treatment.

      Market Dynamics

      Our  researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

      What are the key market drivers leading to the rise In the adoption of Tissue Microarray Industry?

      Growing number of cancer cases worldwide is the key driver of the market.

    • The Tissue Microarray (TMA) market is witnessing significant growth due to its increasing application in molecular pathology, particularly in oncology research. TMAs enable researchers to analyze gene expression, protein localization, and molecular markers in heterogeneous cancers from a large number of cancer patient cases. This information is crucial for identifying biomarkers, clinical outcomes, therapeutic targets, prognostic indicators, and drug efficacy in various clinical settings. Genetic abnormalities play a significant role in tumor development, and TMAs facilitate the analysis of these abnormalities through techniques such as imaging, data analysis, and spectroscopic analysis. Precision medicine and personalized medicine are emerging areas where TMAs are being used extensively for drug development, clinical trials, and biomarker discovery.
    • TMAs are also used in various clinical diagnostics, including immunohistochemistry (IHC), Next-Generation Sequencing (NGS), DNA microarray, and Northern blotting. These techniques enable the analysis of protein expression, mRNA analysis, and protein levels, among others. Automated analysis and high-throughput screening are essential for processing large volumes of data generated through these techniques. The increasing cancer incidence, coupled with the need for accurate and efficient diagnostic methods, is driving the demand for TMAs in healthcare diagnostic facilities. Array-based technology, including TMAs, is revolutionizing cancer research by providing insights into disease genes, comparative genomic hybridization, and sequencing bioinformatics. TMAs are also used in various clinical assessments, such as fluorescent in-situ hybridization, and In the discovery of lead compounds for drug development.
    • TMAs have applications in various fields, including neurology, cardiology, and infectious diseases. They are used for antigen identification, immunostaining, and antibody development. TMAs are also used In the pharmaceutical industry for drug testing and biologics development. Overall, the TMA market is expected to continue growing due to its wide range of applications in molecular pathology and clinical diagnostics.

      • What are the market trends shaping the Tissue Microarray Industry?

      Rising popularity of personalized medicines is the upcoming market trend.

    • Tissue Microarray (TMA) technology plays a pivotal role in molecular pathology, facilitating gene expression and protein localization studies in various clinical settings. In oncology research, TMAs have been instrumental in understanding tumor heterogeneity and identifying biomarkers for clinical outcomes, therapeutic targets, and prognostic indicators. This technology enables high-throughput screening of large numbers of tissue samples using automated analysis, imaging techniques, and data analysis tools. Microarray techniques, including DNA and protein expression analysis, have significantly advanced biomarker discovery and drug development in cancer research. TMAs are used extensively in immunohistochemistry (IHC), Next-Generation Sequencing (NGS), and digital pathology for biomarker research and clinical diagnostics.
    • Sample processing, antibody-based detection, and antigen identification are crucial aspects of TMA-based research. The increasing incidence of cancer and the need for personalized medicine have fueled the growth of the market. The market encompasses various applications, including cancer prevalence assessment, diagnostic methods, and lead discovery. Array-based technology, such as TMAs, plays a significant role In the identification of disease genes and the analysis of heterogeneous cancers in cancer patient cases. Microarray techniques, including proteomics and genomics, have become essential tools for pharmaceutical companies in drug discovery and clinical trials. TMAs are used for drug efficacy testing, biologics development, and fluorescent in-situ hybridization.
    • Frozen tissue arrays and DNA microarrays are increasingly used in research, while NGS and Northern/Western blotting are employed for sequencing bioinformatics and gene expression profiling. In summary, TMA technology is a vital component of molecular diagnostics and biotechnology, enabling the identification and analysis of genetic abnormalities and biomarkers for various diseases, including cancer, neurology, cardiology, and infectious diseases. The technology's ability to facilitate high-throughput screening, automation, and data analysis makes it an essential tool for precision and personalized medicine.

      • What challenges does the Tissue Microarray Industry face during its growth?

      High cost of instruments is a key challenge affecting the industry growth.

    • The Tissue Microarray (TMA) market encompasses the use of advanced technology in molecular pathology for gene expression and protein localization studies. This market caters to oncology research, tumor heterogeneity analysis, and therapeutic targets identification. Biomarkers and clinical outcomes play a significant role in drug efficacy assessment in various clinical settings. Genetic abnormalities and molecular diagnostics are integral to the TMA market, which includes automation, sample throughput, imaging techniques, data analysis, and precision medicine. Biotechnology and pharmaceutical industries are major consumers, driving biomarker research and drug development. TMA is used for cancer prevalence assessment, clinical trials, and antibody development. Protein expression analysis through immunohistochemistry (IHC), Next-Generation Sequencing (NGS), and DNA microarray are essential applications.
    • Automated analysis and comparative genomic hybridization are crucial for lead discovery and clinical assessment. The market growth is driven by the need for high throughput screening, spectroscopic analysis, and drug testing. Biologics, immunostaining, and antigen identification are other applications. Healthcare diagnostic facilities utilize TMA for various diseases, including cancer, neurology, cardiology, and infectious diseases. Microarray techniques, such as Fluorescent in-situ hybridization, are used for frozen tissue array analysis. The TMA market is significant In the context of disease genes, heterogeneous cancers, and cancer patient cases. Proteomics and genomics are essential for understanding cancer burden and diagnostic methods. Array-based technology and disease genes are essential for cancer research, biopsy, and drug discovery.
    • TMA is a vital tool for cancer treatment and clinical assessment.

      • Exclusive Customer Landscape

      The tissue microarray market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the tissue microarray market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

      Tissue Microarray Market Share by Geography

       Customer Landscape

      Key Companies & Market Insights

      Companies are implementing various strategies, such as strategic alliances, tissue microarray market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence In the industry.

      Agilent Technologies Inc. - The company introduces tissue microarrays featuring a genome-wide median probe spacing of 2.1 KB and expanded coverage on key regions, including genes, promoters, miRNAs, PAR, and telomeric areas. This product line, marketed under the brand name SurePrint G3 Human CGH, delivers enhanced precision and comprehensive gene expression analysis.

      The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

      • Agilent Technologies Inc.
      • Arrayit Corp.
      • Bio Rad Laboratories Inc.
      • Bio Techne Corp.
      • Enzo Biochem Inc.
      • Illumina Inc.
      • Molecular Device LLC
      • OriGene Technologies Inc.
      • Pantomics Inc.
      • Perkin Elmer Inc.
      • PhalanxBio Inc.
      • Thermo Fisher Scientific Inc.

      Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

      Research Analyst Overview

      Tissue microarrays (TMAs) have emerged as a valuable tool in molecular pathology, facilitating the analysis of gene expression and protein localization in various clinical settings. These arrays allow for the simultaneous assessment of multiple tissue samples, enabling researchers to investigate tumor heterogeneity and identify biomarkers with potential clinical applications. The use of TMAs in molecular pathology is driven by the growing demand for precision and personalized medicine. TMAs enable the analysis of molecular markers related to genetic abnormalities, clinical outcomes, drug efficacy, and therapeutic targets in various cancer types, including oncology research and prostate cancer. TMAs have been instrumental in advancing our understanding of cancer prevalence and disease progression.

      They have been employed In the discovery and development of biomarkers for various clinical applications, including diagnostics, drug development, and clinical trials. TMAs have also been utilized In the analysis of protein expression, antibodies, and immunostaining, among other techniques. Automation and high-throughput screening have significantly increased the sample throughput and efficiency of TMA-based research. Imaging techniques, such as spectroscopic analysis and digital pathology, have further enhanced the capabilities of TMAs in data analysis and precision medicine. TMAs have applications beyond oncology research, including neurology, cardiology, and infectious diseases. They have been used In the analysis of genetic abnormalities, heterogeneous cancers, and cancer patient cases, as well as In the development of lead discovery and clinical assessment.

      The use of TMAs in molecular diagnostics and biotechnology has led to the identification of disease genes and the development of new diagnostic methods. Array-based technology, including DNA microarray and next-generation sequencing, have been employed In the analysis of tissue samples for various applications, including SNP detection, comparative genomic hybridization, and sequencing bioinformatics. The advancements in TMA technology have significant implications for pharmaceutical companies, biomarker research, and drug development. TMAs have been used in drug testing and the identification of biologics, providing valuable insights into drug discovery applications and cancer treatment. In conclusion, TMAs have become an essential tool in molecular pathology, enabling the analysis of gene expression, protein localization, and molecular markers in various clinical settings.

      The technology's ability to facilitate high-throughput screening, automation, and data analysis has led to significant advancements in cancer research, diagnostics, and drug development. The potential applications of TMAs extend beyond oncology research, making it a valuable technology in various fields of healthcare diagnostic facilities.

      Market Scope

      Report Coverage

      Details

      Page number

      139

      Base year

      2023

      Historic period

      		 2018-2022

      Forecast period

      2024-2028

      Growth momentum & CAGR

      Accelerate at a CAGR of 5.8%

      Market growth 2024-2028

      USD 2247.8 million

      Market structure

      Concentrated

      YoY growth 2023-2024(%)

      5.4

      Key countries

      US, Canada, Germany, China, and UK

      Competitive landscape

      Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks

      Request Free Sample

      What are the Key Data Covered in this Tissue Microarray Market Research and Growth Report?

      • CAGR of the Tissue Microarray industry during the forecast period
      • Detailed information on factors that will drive the growth and forecasting between 2024 and 2028
      • Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
      • Accurate predictions about upcoming growth and trends and changes in consumer behaviour
      • Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
      • Thorough analysis of the market’s competitive landscape and detailed information about companies
      • Comprehensive analysis of factors that will challenge the tissue microarray market growth of industry companies

      We can help! Our analysts can customize this tissue microarray market research report to meet your requirements.

      Get in touch

       

      Table of Contents not available.

      Research Methodology

      Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

      INFORMATION SOURCES

      Primary sources

      • Manufacturers and suppliers
      • Channel partners
      • Industry experts
      • Strategic decision makers

      Secondary sources

      • Industry journals and periodicals
      • Government data
      • Financial reports of key industry players
      • Historical data
      • Press releases

      DATA ANALYSIS

      Data Synthesis

      • Collation of data
      • Estimation of key figures
      • Analysis of derived insights

      Data Validation

      • Triangulation with data models
      • Reference against proprietary databases
      • Corroboration with industry experts

      REPORT WRITING

      Qualitative

      • Market drivers
      • Market challenges
      • Market trends
      • Five forces analysis

      Quantitative

      • Market size and forecast
      • Market segmentation
      • Geographical insights
      • Competitive landscape

      Interested in this report?

      Get your sample now to see our research methodology and insights!

      Download Now

      Frequently Asked Questions

      Tissue Microarray market growth will increase by $ 2247.8 mn during 2024-2028.

      The Tissue Microarray market is expected to grow at a CAGR of 5.8% during 2024-2028.

      Tissue Microarray market is segmented by End-user( Hospitals, Clinics, Diagnostics centers)

      Agilent Technologies Inc., Arrayit Corp., Bio Rad Laboratories Inc., Bio Techne Corp., Enzo Biochem Inc., Illumina Inc., Molecular Device LLC, OriGene Technologies Inc., Pantomics Inc., Perkin Elmer Inc., PhalanxBio Inc., Thermo Fisher Scientific Inc. are a few of the key vendors in the Tissue Microarray market.

      North America will register the highest growth rate of 34% among the other regions. Therefore, the Tissue Microarray market in North America is expected to garner significant business opportunities for the vendors during the forecast period.

      US, Canada, Germany, China, UK

      • Growing number of cancer cases worldwideThe prevalence of cancer is increasing across the world due to various reasons is the driving factor this market.
      • including an unhealthy diet is the driving factor this market.
      • lack of physical activity is the driving factor this market.
      • tobacco use is the driving factor this market.
      • and excessive alcohol consumption. Tumor development involves simultaneous changes in thousands of cells and variations in genes. According to the International Agency for Research on Cancer (IARC) is the driving factor this market.
      • 20% of people develop cancer during their lifetime globally is the driving factor this market.
      • and 12.5% of men and 9.09% of women die from the disease. A rise in the elderly population around the globe and socio-economic risk factors are the primary factors driving the increase in the prevalence of various carcinomas. Breast cancer is among the most common cancers diagnosed among women globally. Colorectal is the driving factor this market.
      • lung is the driving factor this market.
      • cervical is the driving factor this market.
      • and thyroid cancers are also common among women. On December 14 is the driving factor this market.
      • 2020 is the driving factor this market.
      • the IARC released an updated Globocan 2020 report is the driving factor this market.
      • which stated that global cancer cases rose to 19.3 million in 2020 is the driving factor this market.
      • along with 10 million associated deaths. Moreover is the driving factor this market.
      • the US National Cancer Institute estimates that by 2030 is the driving factor this market.
      • the number of cancer cases and deaths globally is expected to be 21.6 million and 13.5 million is the driving factor this market.
      • respectively. Such a rise in the number of cancer cases and the resultant research and development on cures and early diagnosis of the disease will drive the demand for tissue microarrays during the forecast period. is the driving factor this market.

      The Tissue Microarray market vendors should focus on grabbing business opportunities from the Hospitals segment as it accounted for the largest market share in the base year.